Adult

Meropenem

Warning

General Information

Formulary antimicrobial: Use in accordance with Trust guidelines. All other indications must be recommended/prescribed by a Micro/ID consultant or registrar. 

AWaRe antibiotic classification: 'Reserve'. All indications to be discussed with Micro/ID.

For adult critical care areas only: Where using meropenem by continuous Infusion see Adult Intensive Care Medication Guidelines

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF

Standard Dose

 

Intravenous dose

Standard dose

500mg tds

Sepsis or Severe infections or Pseudomonas aeruginosa infections

1g tds

CNS infection

2g tds

Obesity

No dose adjustment required.

Renal and hepatic impairment

Renal impairment

 

eGFR

(mL/min/1.73m2)

Where usual dose would be 

500mg TDS meropenem

Where usual dose would be 

1g TDS meropenem

Where usual dose would be 

2g TDS meropenem

Over 50

No dose adjustment required

No dose adjustment required

No dose adjustment required

26-50

500mg BD

1g BD 

2g BD 

10-25

500mg BD

500mg TDS

1g BD 

less than 10

500mg OD

1g OD

1g OD

HD/HDF/High Flux/PD

Dose as in eGFR less than 10ml/min/1.73m2.

Dialysed; give after dialysis

 

Hepatic impairment

No dose adjustment necessary but monitor LFTs closely. 

MHRA Drug Safety Alerts

MHRA Drug Safety Update (December 2014) Carbapenems: concomitant use with valproic acid not recommended 

  • There is a clinically significant interaction between carbapenems and sodium valproate or valproic acid, which results in reduced valproate plasma concentrations with potential for inadequate seizure control.
  • If the patient is already prescribed sodium valproate or valproic acid and meropenem is recommended, discuss with Micro/ID and the relevant clinical team. 
  • OUH Weekly Safety Message 365 about Interaction between Sodium Valproate and Carbapenem Antibiotics can be found HERE (February 2026)

References

  1. Pfizer Limited. Meronem IV 1g Powder for Solution for Injection or Infusion summary of product characteristics. Electronic medicines compendium. Last revision of the text 09/25. Accessed via www.medicines.org.uk Accessed 16/2/26
  2. The Renal Drug Database. Meropenem. Last updated 28/10/24. Accessed via https://www.renaldrugdatabase.com Accessed 16/2/26
  3. British National Formulary. Meropenem. BNF online accessed via www.medicinescomplete.com  Accessed 16/2/26.
  4. MHRA. Drug Safety update (December 2014). Carbapenems: concomitant use with valproic acid not recommended. Accessed at https://www.gov.uk/drug-safety-update/carbapenems-concomitant-use-with-valproic-acid-not-recommended
  5. Sanford Guide [online]. Meropenem. Last updated: 30/1/26. Accessed via https://webedition.sanfordguide.com Accessed 16/2/26
  6. All-Wales Antimicrobial Pharmacists’ Group (2022). Antimicrobial dosing in extremes of body weight in adults. Accessed 16/2/26.

Editorial Information

Last reviewed: 02 Mar 2026

Next review date: 01 Mar 2029

Author(s): AMST.